Results 251 to 260 of about 1,820,478 (344)

Bio‐Responsive Hydrogel for Targeted on‐Demand Release of a Phage Cocktail for Treatment of Pseudomonas aeruginosa Infection

open access: yesAdvanced Functional Materials, EarlyView.
This study presents an injectable hydrogel that responds to Pseudomonas aeruginosa infection by releasing a dual‐phage cocktail on demand. The system degrades selectively in infected wounds, enhances phage localization and stability, and shows potent antibiofilm activity and biocompatibility in an ex vivo human skin model—offering a promising strategy ...
Siyuan Tao   +9 more
wiley   +1 more source

From Exciton Dynamics to Cell Fate: A Carbon Dot Based NIR Photocatalytic Platform for Pyroptosis via Self‐Trapped Excitons

open access: yesAdvanced Functional Materials, EarlyView.
A facile and effective method to boost NIR light induced photocatalysis based on nontoxic NIR emissive carbon dots (nir‐CDs) via Self‐trapped excitons, showing that both O2− • and •OH can be generated from nir‐CDs under NIR laser irradiation. Abstract Near‐infrared (NIR) light‐triggered photocatalytic therapy remains a critical challenge in efficient ...
Qingcheng Wang   +8 more
wiley   +1 more source

Prognostic impact of non-clear cell histology on recurrence and cancer-free survival in renal cell carcinoma: a time-to-event analysis. [PDF]

open access: yesBMC Urol
Tayeb W   +8 more
europepmc   +1 more source

DENTA: A Dual Enzymatic Nanoagent for Self‐Activating Tooth Whitening and Biofilm Disruption

open access: yesAdvanced Functional Materials, EarlyView.
The nanoapatite with dual enzymes (DENTA) accumulates in dentinal tubules, reducing hypersensitivity caused by dental nerve exposure and facilitating continuous ROS generation through salivary glucose for effective, long‐term whitening. The dentin structures remain non‐destructive due to the low concentration of ROS, demonstrating excellent cell ...
Junseok Kim   +13 more
wiley   +1 more source

Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma. [PDF]

open access: yesCommun Med (Lond)
Versluis JM   +15 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy